176 related articles for article (PubMed ID: 17931087)
61. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
62. Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia.
Matherly LH; Taub JW
Leuk Lymphoma; 1996 May; 21(5-6):359-68. PubMed ID: 9172800
[TBL] [Abstract][Full Text] [Related]
63. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma.
Shimasaki N; Mori T; Torii C; Sato R; Shimada H; Tanigawara Y; Kosaki K; Takahashi T
J Pediatr Hematol Oncol; 2008 May; 30(5):347-52. PubMed ID: 18458567
[TBL] [Abstract][Full Text] [Related]
64. Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia.
Mousavian Z; Nowzari-Dalini A; Stam RW; Rahmatallah Y; Masoudi-Nejad A
Cell Oncol (Dordr); 2017 Feb; 40(1):33-45. PubMed ID: 27798768
[TBL] [Abstract][Full Text] [Related]
65. Pharmacogenetic studies in children with acute lymphoblastic leukemia in Argentina.
Aráoz HV; D'Aloi K; Foncuberta ME; Sanchez La Rosa CG; Alonso CN; Chertkoff L; Felice M
Leuk Lymphoma; 2015 May; 56(5):1370-8. PubMed ID: 25110820
[TBL] [Abstract][Full Text] [Related]
66. Asparagine synthetase (ASNS) gene polymorphism is associated with the outcome of childhood acute lymphoblastic leukemia by affecting early response to treatment.
Pastorczak A; Fendler W; Zalewska-Szewczyk B; Górniak P; Lejman M; Trelińska J; Walenciak J; Kowalczyk J; Szczepanski T; Mlynarski W;
Leuk Res; 2014 Feb; 38(2):180-3. PubMed ID: 24268318
[TBL] [Abstract][Full Text] [Related]
67. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia.
Styczynski J; Pieters R; Huismans DR; Schuurhuis GJ; Wysocki M; Veerman AJ
Br J Haematol; 2000 Sep; 110(4):813-8. PubMed ID: 11054062
[TBL] [Abstract][Full Text] [Related]
68. Drug-resistance Profile in Multiple-relapsed Childhood Acute Lymphoblastic Leukemia.
Pogorzala M; Kubicka M; Rafinska B; Wysocki M; Styczynski J
Anticancer Res; 2015 Oct; 35(10):5667-70. PubMed ID: 26408741
[TBL] [Abstract][Full Text] [Related]
69. [Application of genome editing technology for the validation of pharmacogenomics in acute lymphoblastic leukemia].
Akahane K
Rinsho Ketsueki; 2022; 63(11):1566-1579. PubMed ID: 36476799
[TBL] [Abstract][Full Text] [Related]
70. Impact of glutathione S-transferase gene deletion on early relapse in childhood B-precursor acute lymphoblastic leukemia.
Takanashi M; Morimoto A; Yagi T; Kuriyama K; Kano G; Imamura T; Hibi S; Todo S; Imashuku S
Haematologica; 2003 Nov; 88(11):1238-44. PubMed ID: 14607752
[TBL] [Abstract][Full Text] [Related]
71. Ancestry and pharmacogenetics of antileukemic drug toxicity.
Kishi S; Cheng C; French D; Pei D; Das S; Cook EH; Hijiya N; Rizzari C; Rosner GL; Frudakis T; Pui CH; Evans WE; Relling MV
Blood; 2007 May; 109(10):4151-7. PubMed ID: 17264302
[TBL] [Abstract][Full Text] [Related]
72. Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia.
Styczynski J; Wysocki M; Debski R; Czyzewski K; Kolodziej B; Rafinska B; Kubicka M; Koltan S; Koltan A; Pogorzala M; Kurylak A; Olszewska-Slonina D; Balwierz W; Juraszewska E; Wieczorek M; Olejnik I; Krawczuk-Rybak M; Kuzmicz M; Kowalczyk J; Stefaniak J; Badowska W; Sonta-Jakimczyk D; Szczepanski T; Matysiak M; Malinowska I; Stanczak E; Wachowiak J; Konatkowska B; Gil L; Balcerska A; Maciejka-Kapuscinska L
J Cancer Res Clin Oncol; 2007 Nov; 133(11):875-93. PubMed ID: 17671794
[TBL] [Abstract][Full Text] [Related]
73. Acute lymphoblastic leukaemia.
Pui CH; Robison LL; Look AT
Lancet; 2008 Mar; 371(9617):1030-43. PubMed ID: 18358930
[TBL] [Abstract][Full Text] [Related]
74. Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia.
Pieters R; Klumper E; Kaspers GJ; Veerman AJ
Crit Rev Oncol Hematol; 1997 Jan; 25(1):11-26. PubMed ID: 9134309
[No Abstract] [Full Text] [Related]
75. [Cytogenetics and in vitro drug resistance of acute leukemia in children and adults].
Styczyński J; Haus O
Postepy Hig Med Dosw (Online); 2006; 60():527-37. PubMed ID: 17060894
[TBL] [Abstract][Full Text] [Related]
76. Acute lymphoblastic leukemia.
Pui CH; Relling MV; Downing JR
N Engl J Med; 2004 Apr; 350(15):1535-48. PubMed ID: 15071128
[No Abstract] [Full Text] [Related]
77. The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions.
Bhatla T; Jones CL; Meyer JA; Vitanza NA; Raetz EA; Carroll WL
J Pediatr Hematol Oncol; 2014 Aug; 36(6):413-8. PubMed ID: 24942023
[TBL] [Abstract][Full Text] [Related]
78. Molecular diagnostics in the treatment of childhood acute lymphoblastic leukemia.
Rubnitz JE
J Biol Regul Homeost Agents; 2000; 14(3):182-6. PubMed ID: 11037050
[TBL] [Abstract][Full Text] [Related]
79. Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: a meta-analysis.
He HR; Liu P; He GH; Dong WH; Wang MY; Dong YL; Lu J
Leuk Lymphoma; 2014 Dec; 55(12):2793-800. PubMed ID: 24597986
[TBL] [Abstract][Full Text] [Related]
80. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia.
Eckert C; Biondi A; Seeger K; Cazzaniga G; Hartmann R; Beyermann B; Pogodda M; Proba J; Henze G
Lancet; 2001 Oct; 358(9289):1239-41. PubMed ID: 11675066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
